હેસ્ટર બાયોસાયન્સ શેર કિંમત

Pharmaceuticals company Hester Biosciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations for Q4FY26 was reported at Rs 1,001.10 million, reflecting a 22.20% YoY increase from Rs 819.25 million in Q4FY25, and a 29.32% QoQ growth from Rs 774.15 million in Q3FY26. Total Income for Q4FY26 stood at Rs 970.82 million, up 29.49% YoY from Rs 749.75 million in Q4FY25, and an increase of 24.33% QoQ from Rs 780.84 million in Q3FY26. EBITDA for Q4FY26 stood at Rs 360.97 million, a robust growth of 167% YoY compared to Rs 135.41 million in Q4FY25. Profit After Tax (PAT) for Q4FY26 soared by 973.72% YoY to Rs 165.46 million from Rs 15.41 million in Q4FY25, and climbed 77.72% QoQ from Rs 93.10 million in Q3FY26. For the full year FY26, Revenue from Operations was Rs 3,325.99 million, growing by 6.91% YoY from Rs 3,111.02 million in FY25. Total Income for FY26 reached Rs 3,422.83 million, up 8.65% YoY from Rs 3,150.26 million in FY25. Profit After Tax (PAT) for FY26 demonstrated a strong 99.42% YoY growth, closing at Rs 574.84 million compared to Rs 288.26 million in FY25. Standalone Financial Highlights: Revenue from Operations for Q4FY26 stood at Rs 937.13 million, registering a growth of 22.23% YoY compared to Rs 766.72 million in Q4FY25, and an increase of 33.20% QoQ from Rs 703.54 million in Q3FY26. Total Income for Q4FY26 was Rs 978.92 million, up 25.93% YoY from Rs 777.30 million in Q4FY25, and up 37.12% QoQ from Rs 713.89 million in Q3FY26. EBITDA for Q4FY26 witnessed significant growth, reaching Rs 426.40 million, an increase of 189% YoY from Rs 147.60 million in Q4FY25. Profit After Tax (PAT) for Q4FY26 surged by 173.83% YoY to Rs 263.84 million against Rs 96.35 million in Q4FY25, and grew by 147.30% QoQ from Rs 106.69 million in Q3FY26. For the full year FY26, Revenue from Operations was Rs 2,921.36 million, a growth of 1.98% YoY from Rs 2,864.66 million in FY25. Total Income for FY26 stood at Rs 2,997.71 million, an increase of 2.93% YoY from Rs 2,912.30 million in FY25. Profit After Tax (PAT) for FY26 jumped by 63.62% YoY to Rs 521.00 million, up from Rs 318.42 million in FY25. Business & Segment Highlights: Poultry Healthcare Division: Recorded strong growth during Q4FY26 with revenues of Rs 650.20 million, up 41% YoY from Rs 460.85 million in Q4FY25. For FY26, revenue stood at Rs 2,060.79 million, up 24% YoY from Rs 1,664.39 million in FY25. Growth was supported by improved market penetration, expanded placements, and sustained demand for vaccines. Animal Healthcare Division: Q4FY26 revenue stood at Rs 286.41 million, declining 6% YoY from Rs 305.37 million in Q4FY25. FY26 revenue was Rs 818.32 million, down 32% YoY from Rs 1,198.83 million in FY25. The division continued to be impacted by delays in government immunisation programmes and uneven demand across certain commercial markets. Dividend: The Board of Directors recommended a dividend of Rs 11 per equity share of Rs 10 each (110%) for the financial year 2025-26. Divestment: The Board approved the divestment of a 43.81% equity shareholding (out of its 54.81% stake) in its subsidiary, Texas Lifescience Private Limited (TLPL), by transferring 2,163,377 equity shares at Rs 42.34 per share. Consequently, TLPL ceased to be a subsidiary from 27 March 2026. Operational Updates: During the quarter, the company capitalised its BSL 3 facility as part of its ongoing capacity expansion and infrastructure strengthening initiatives. It also received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine, strengthening its poultry vaccine portfolio. Profitability Drivers: Gross profit margins improved to 78% in Q4FY26 and 72% for the full year FY26, supported by a favourable product mix and continued operational discipline. EBITDA and PAT growth were driven by a stronger contribution from the Poultry Healthcare Division and continued cost optimisation initiatives. Overseas Operations: Overseas markets witnessed mixed conditions, though the company strengthened its presence across selected African and export markets. The company also continued its participation in the GALVmed-led VITAL 2 programme focused on vaccine awareness and adoption in Africa. Re-appointment: The Board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a period of 3 years, effective from 28 October 2026. Result PDF

• ટ્રેન્ડલાઇન
• 3 અઠવાડિયા 5 દિવસ પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની હેસ્ટર બાયોસાયન્સે Q3FY26 પરિણામોની આવકની જાહેરાત કરી: Q3FY25 દરમિયાન ₹ 632.18 મિલિયન સામે ₹ 774.15 મિલિયન, ફેરફાર 22%. ઇબીઆઇટીડીએ: Q3FY25 દરમિયાન ₹ 138.45 મિલિયન સામે ₹ 197.77 મિલિયન, 43% બદલો. EBITDA માર્જિન: Q3FY26 માટે 26%. પીએટી: Q3FY25 દરમિયાન ₹ 114.08 મિલિયન સામે ₹ 93.1 મિલિયન, -18% બદલો. PAT માર્જિન: Q3FY26 માટે 12%. ઇપીએસ: Q3FY26 માટે 10.94. પોલ્ટ્રી હેલ્થકેર ડિવિઝને Q3 FY26 માં 32% વૃદ્ધિ અને 9M FY26 માં 17% વૃદ્ધિ પ્રદાન કરી, જે બજારની ઊંડાણ, સુધારેલ પ્લેસમેન્ટ અને અમારી રસીઓની સતત માંગને કારણે પ્રેરિત છે. એનિમલ હેલ્થકેર ડિવિઝનમાં Q3 FY26 માં 38% ઘટાડો નોંધાયો હતો અને 9M FY26 માં 40% ઘટાડો નોંધાયો હતો, મુખ્યત્વે રુમિનન્ટ સેગમેન્ટમાં સરકારી-નેતૃત્વવાળા ઇમ્યુનાઇઝેશન કાર્યક્રમોમાં વિલંબને કારણે, ખાસ કરીને PPR અને બકરીના પોક્સ (લમ્પી સ્કિન રોગ સામે ઇમ્યુનાઇઝ કરવા માટે). પરિણામની PDF

• ટ્રેન્ડલાઇન
• 4 મહિના 1 અઠવાડિયા પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની હેસ્ટર બાયોસાયન્સે Q2FY26 કામગીરીમાંથી આવકની જાહેરાત કરી: Q2FY25 દરમિયાન ₹836.92 મિલિયન સામે ₹709.69 મિલિયન, -15% બદલો. ઇબીઆઇટીડીએ: Q2FY25 દરમિયાન ₹ 219.55 મિલિયન સામે ₹ 235.97 મિલિયન, 7% બદલો. EBITDA માર્જિન: Q2FY26 માટે 33%. પીએટી: Q2FY25 દરમિયાન ₹ 83.91 મિલિયન સામે ₹ 143.31 મિલિયન, 71% બદલો. PAT માર્જિન: Q2FY26 માટે 20%. ઇપીએસ: Q2FY26 માટે ₹ 16.85. પરિણામની PDF

• ટ્રેન્ડલાઇન
• 6 મહિના 4 અઠવાડિયા પહેલાં